医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IONTAS Signs Collaboration Agreement With LG Chem, Ltd. to Identify Therapeutic Oncology Leads

2018年06月05日 PM06:54
このエントリーをはてなブックマークに追加


 

CAMBRIDGE, England & SEOUL, South Korea

IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has signed a collaboration agreement with Korean-based LG Chem, Ltd. for the discovery of therapeutic antibodies targeting undisclosed targets for use in the treatment of cancers. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by LG Chem, Ltd. and to further prove the biological activity of the antibodies.

Dr Neil Butt, CBO of IONTAS, said: “This new agreement marks IONTAS’ expansion into the Asian market, and we are delighted to have been selected by LG Chem, Ltd., after a rigorous diligence process. The application of our proprietary technologies will assist LG Chem, Ltd. in expanding its current therapeutic pipeline by generating leads against pre-defined specifications agreed at the project outset.”

Dr Myung Jin Kim, Executive Vice President / R&D Leader, Life Sciences R&D of LG Chem, Ltd., said: “IONTAS was selected because of its robust track record and technical know-how. We feel confident this collaboration will result in a strong panel of therapeutic leads which will help develop our oncology pipeline.”

Dr Neil Butt and Dr Mike Dyson, CTO of IONTAS, will attend the 2018 BIO International Convention (Boston, MA) from June 4 – 7 and Dr John McCafferty, CEO and Founder of IONTAS, will be at Antibody Engineering and Therapeutics Europe (Amsterdam, NL) from 5 – 7 June.

For further information, please visit https://www.iontas.co.uk/technologies/

ENDS

For a high-resolution image please contact lorna.cuddon@zymecommunications.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20180605005820/en/

CONTACT

IONTAS Ltd
Neil Butt, Chief Business Officer
Tel: +44
1223 750801
bd@iontas.co.uk
or
Zyme
Communications

Lorna Cuddon
Tel: +44 (0)1223 968 920
lorna.cuddon@zymecommunications.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application
  • 火山噴火で家屋の破壊と住民の避難が続く中、ハワイ・コミュニティ財団が支援基金を創設
  • Octapharma宣布Nuwiq®产品新增剂量规格在欧洲获准,提高了血友病A患者的给药灵活性
  • PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始
  • LG化学举办“全球创新大赛 (GIC)”“寻找改变世界的创新技术”